Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 42-year-old woman comes to the clinic for a routine follow-up. Eighteen months ago, she underwent a lumpectomy and adjuvant radiation therapy for an estrogen receptor-positive, progesterone receptor-positive, HER2-negative invasive ductal carcinoma of the right breast. She has been taking tamoxifen since completing radiation therapy. Three weeks ago, she visited an urgent care clinic for new-onset anhedonia, persistent low mood, and severe hot flashes that frequently interrupted her sleep. She was diagnosed with major depressive disorder and prescribed fluoxetine. Today, the patient reports a mild improvement in her mood but states the hot flashes remain highly bothersome. Additionally, she expresses concern after reading an article online about potential interactions between her medications. Vital signs are within normal limits. Physical examination is unremarkable. Which of the following is the most appropriate pharmacologic intervention for this patient?

  1. Discontinue fluoxetine and initiate venlafaxineAnswer
  2. B
    Discontinue fluoxetine and initiate bupropion
  3. C
    Discontinue tamoxifen and initiate anastrozole
  4. D
    Maintain the current regimen and increase the tamoxifen dose
  5. E
    Continue the current regimen and add a low-dose transdermal estradiol patch

Answer

The most appropriate intervention is to discontinue fluoxetine and initiate venlafaxine.
The correct answer addresses both the dangerous drug-drug interaction and the patient's symptoms. Tamoxifen is a selective estrogen receptor modulator (SERM) that acts as a prodrug. It must be metabolized by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme into its highly active metabolite, endoxifen. Fluoxetine, paroxetine, and bupropion are potent CYP2D6 inhibitors. Coadministration of these agents with tamoxifen significantly lowers endoxifen levels, severely compromising the efficacy of the breast cancer treatment and increasing the risk of recurrence. The offending agent (fluoxetine) must be stopped. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that is highly effective for both major depressive disorder and tamoxifen-induced vasomotor symptoms (hot flashes). Crucially, venlafaxine is only a weak inhibitor of CYP2D6 and does not clinically interfere with tamoxifen activation, making it the safest and most effective choice.

Step-by-Step Solution

1
Identify the critical drug-drug interaction in the current regimen.
The patient is taking tamoxifen (a prodrug) and fluoxetine (a strong CYP2D6 inhibitor).
Tamoxifen requires activation by CYP2D6 to its active metabolite, endoxifen. Fluoxetine blocks this enzyme, rendering tamoxifen ineffective and increasing breast cancer recurrence risk.
2
Determine the therapeutic needs of the patient.
The patient requires ongoing adjuvant endocrine therapy for breast cancer, treatment for major depressive disorder, and management of severe vasomotor symptoms (hot flashes).
A holistic approach must address both the oncologic requirements and the patient's symptomatic psychiatric and menopausal-like complaints.
3
Select a medication that meets all therapeutic needs without causing detrimental interactions.
Venlafaxine is selected as the replacement therapy.
Venlafaxine is an SNRI that effectively treats depression, is widely recognized as a first-line non-hormonal treatment for tamoxifen-induced hot flashes, and lacks significant CYP2D6 inhibitory activity.

Key Concept

Tamoxifen is a prodrug activated by CYP2D6; strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) must be avoided to prevent compromising breast cancer treatment efficacy. Venlafaxine is the preferred alternative for treating concomitant depression and hot flashes.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic